What are the odds of Ampio Pharmaceuticals to dip in December?


USD 0.39  0.0173  4.22%   

Ampio Pharmaceuticals Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 98.79 Million. The current year Invested Capital is expected to grow to about 436.2 K, whereas Average Assets are forecasted to decline to about 26.2 M. As many millenniums are excited about healthcare space, it is only fair to digest Ampio Pharmaceuticals. We will cover the possibilities of making Ampio Pharmaceuticals into a steady grower in December. Here I will also expose some primary fundamental factors affecting Ampio Pharmaceuticals' services, and outline how it will impact the outlook for investors this year.
Published six days ago
View all stories for Ampio Pharm | View All Stories
The company reported the previous year's revenue of 1.16 M. Net Loss for the year was (17.56 M) with profit before overhead, payroll, taxes, and interest of 458.96 K.

Watch out for price decline

Please consider monitoring Ampio Pharm on a daily basis if you are holding a position in it. Ampio Pharm is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Ampio Pharm stock to be traded above the $1 level to remain listed. If Ampio Pharm stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Ampio Pharm's Liquidity

Ampio Pharm financial leverage refers to using borrowed capital as a funding source to finance Ampio Pharm ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ampio Pharm financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Ampio Pharm's total debt and its cash.

How does Ampio utilize its cash?

To perform a cash flow analysis of Ampio Pharm, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Ampio Pharm is receiving and how much cash it distributes out in a given period. The Ampio Pharm cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Ampio Pharm Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (14.09 Million)

Going after Ampio Financials

Ampio Pharmaceuticals holds a total of two hundred twenty-seven million one hundred thirty thousand outstanding shares. Ampio Pharmaceuticals shows 7.51 percent if its outstanding shares held by insiders and 7.51 percent owned by other corporate entities . Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Breakdown

Retail Investors
Retail Investors78.77

Ampio Pharmaceuticals latest price dip can leaving shareholders with little time to react

Ampio Pharmaceuticals latest potential upside ascents over 17.14. Ampio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ampio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Ampio Pharmaceuticals volatility. Ampio Pharmaceuticals is a potential penny stock. Although Ampio Pharmaceuticals may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Ampio Pharmaceuticals. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Ampio instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Although few other entities in the biotechnology industry are either recovering or due for a correction, Ampio Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 23rd of November 2022, we see that Ampio Pharmaceuticals moves completely opposite to the market. The firm is undervalued with close to average probability of financial unrest within the next 24 months. However, our current 90 days 'Buy-Sell' recommendation on the firm is Strong Sell.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Ampio Pharm. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com